ASH
Researchers Test Single-Cell Whole-Genome Sequencing to Select Therapy in Relapsed Multiple Myeloma
Premium
At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.
Genetic Variant in South American Indigenous Population Linked to Better Blood Cancer Drug Response
Premium
The variant, present in the NFKB1 gene and common in the Aymara community, could help guide treatment decisions, researchers reported at ASH.
MRD Negativity After Lymphoma Therapy Predicted Outcomes Better Than Single PET-CT Scan in Study
Premium
Researchers concluded based on data shared at ASH that ctDNA testing can accurately predict who can forgo salvage therapy and may limit the number of tests.
Variant Screening Tool Flags Possible Pathogenic Germline Variants in Multiple Myeloma Patients
Premium
The tool developed by Mount Sinai researchers is designed to identify variants associated with heritable cancer risk within somatic genetic sequencing results.
Circulating Tumor DNA Helps ID First-Line Lymphoma Patients for Roche's Columvi, R-CHOP
Patients whose lymphomas were considered high-risk according to ctDNA analyses were less likely to benefit from the widely used chemotherapy regimen.